Hester Biosciences Limited
Hester Biosciences Limited manufactures and trades in veterinary vaccines and animal health products in India and internationally. It operates through the Poultry Healthcare and Animal Healthcare segments. The company provides poultry vaccines for newcastle disease, infectious bronchitis, infectious bursal, fowl pox, marek's disease, infectious coryza, fowl cholera, inclusion body hepatitis, fowl… Read more
Hester Biosciences Limited (HESTERBIO) - Net Assets
Latest net assets as of September 2025: ₹3.51 Billion INR
Based on the latest financial reports, Hester Biosciences Limited (HESTERBIO) has net assets worth ₹3.51 Billion INR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₹6.75 Billion) and total liabilities (₹3.24 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₹3.51 Billion |
| % of Total Assets | 51.99% |
| Annual Growth Rate | 18.19% |
| 5-Year Change | 38.44% |
| 10-Year Change | 211.65% |
| Growth Volatility | 20.99 |
Hester Biosciences Limited - Net Assets Trend (2006–2025)
This chart illustrates how Hester Biosciences Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Hester Biosciences Limited (2006–2025)
The table below shows the annual net assets of Hester Biosciences Limited from 2006 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | ₹3.27 Billion | +7.85% |
| 2024-03-31 | ₹3.03 Billion | +3.59% |
| 2023-03-31 | ₹2.92 Billion | +9.35% |
| 2022-03-31 | ₹2.67 Billion | +13.32% |
| 2021-03-31 | ₹2.36 Billion | +14.27% |
| 2020-03-31 | ₹2.06 Billion | +13.99% |
| 2019-03-31 | ₹1.81 Billion | +24.93% |
| 2018-03-31 | ₹1.45 Billion | +16.76% |
| 2017-03-31 | ₹1.24 Billion | +18.49% |
| 2016-03-31 | ₹1.05 Billion | +24.99% |
| 2015-03-31 | ₹838.58 Million | +9.92% |
| 2014-03-31 | ₹762.88 Million | +11.38% |
| 2013-03-31 | ₹684.95 Million | +12.18% |
| 2012-03-31 | ₹610.60 Million | +27.25% |
| 2011-03-31 | ₹479.85 Million | +17.43% |
| 2010-03-31 | ₹408.64 Million | +11.51% |
| 2009-03-31 | ₹366.47 Million | +9.49% |
| 2008-03-31 | ₹334.69 Million | +19.76% |
| 2007-03-31 | ₹279.47 Million | +104.77% |
| 2006-03-31 | ₹136.48 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Hester Biosciences Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 237086000000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₹2.37 Billion | 75.44% |
| Common Stock | ₹85.07 Million | 2.71% |
| Other Comprehensive Income | ₹511.55 Million | 16.28% |
| Other Components | ₹175.07 Million | 5.57% |
| Total Equity | ₹3.14 Billion | 100.00% |
Hester Biosciences Limited Competitors by Market Cap
The table below lists competitors of Hester Biosciences Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Chunghwa Chemical Synthesis & Biotech Co Ltd
TW:1762
|
$40.94 Million |
|
Petra Diamonds Limited
PINK:PDLMF
|
$40.95 Million |
|
SIFCO Industries Inc
NYSE MKT:SIF
|
$40.95 Million |
|
Heungkuk F&M I
KO:000540
|
$40.96 Million |
|
Sajodongaone Co Ltd
KO:008040
|
$40.93 Million |
|
Suria Capital Holdings Bhd
KLSE:6521
|
$40.92 Million |
|
MIRA Pharmaceuticals, Inc. Common Stock
NASDAQ:MIRA
|
$40.88 Million |
|
Joinsoon Electronics MFG Co Ltd
TWO:3322
|
$40.88 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Hester Biosciences Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,917,930,000 to 3,142,550,000, a change of 224,620,000 (7.7%).
- Net income of 274,880,000 contributed positively to equity growth.
- Dividend payments of 51,680,000 reduced retained earnings.
- Other comprehensive income increased equity by 4,649,999.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₹274.88 Million | +8.75% |
| Dividends Paid | ₹51.68 Million | -1.64% |
| Other Comprehensive Income | ₹4.65 Million | +0.15% |
| Other Changes | ₹-3.23 Million | -0.1% |
| Total Change | ₹- | 7.70% |
Book Value vs Market Value Analysis
This analysis compares Hester Biosciences Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.65x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 60.51x to 3.65x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-03-31 | ₹23.40 | ₹1416.00 | x |
| 2007-03-31 | ₹40.31 | ₹1416.00 | x |
| 2008-03-31 | ₹42.98 | ₹1416.00 | x |
| 2009-03-31 | ₹47.06 | ₹1416.00 | x |
| 2010-03-31 | ₹52.48 | ₹1416.00 | x |
| 2011-03-31 | ₹61.62 | ₹1416.00 | x |
| 2012-03-31 | ₹70.60 | ₹1416.00 | x |
| 2013-03-31 | ₹93.38 | ₹1416.00 | x |
| 2014-03-31 | ₹88.18 | ₹1416.00 | x |
| 2015-03-31 | ₹96.86 | ₹1416.00 | x |
| 2016-03-31 | ₹118.39 | ₹1416.00 | x |
| 2017-03-31 | ₹140.61 | ₹1416.00 | x |
| 2018-03-31 | ₹165.32 | ₹1416.00 | x |
| 2019-03-31 | ₹208.61 | ₹1416.00 | x |
| 2020-03-31 | ₹236.36 | ₹1416.00 | x |
| 2021-03-31 | ₹268.38 | ₹1416.00 | x |
| 2022-03-31 | ₹305.62 | ₹1416.00 | x |
| 2023-03-31 | ₹343.70 | ₹1416.00 | x |
| 2024-03-31 | ₹343.01 | ₹1416.00 | x |
| 2025-03-31 | ₹387.44 | ₹1416.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Hester Biosciences Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 8.75%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 8.84%
- • Asset Turnover: 0.48x
- • Equity Multiplier: 2.08x
- Recent ROE (8.75%) is below the historical average (15.94%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | 32.57% | 22.13% | 0.89x | 1.65x | ₹30.80 Million |
| 2007 | 18.43% | 23.60% | 0.34x | 2.28x | ₹23.57 Million |
| 2008 | 21.04% | 21.57% | 0.48x | 2.05x | ₹36.94 Million |
| 2009 | 12.92% | 15.70% | 0.40x | 2.03x | ₹10.72 Million |
| 2010 | 14.76% | 16.07% | 0.46x | 1.98x | ₹19.47 Million |
| 2011 | 15.83% | 18.10% | 0.47x | 1.86x | ₹27.97 Million |
| 2012 | 12.73% | 15.76% | 0.51x | 1.60x | ₹16.33 Million |
| 2013 | 13.76% | 14.22% | 0.53x | 1.84x | ₹25.29 Million |
| 2014 | 12.60% | 13.69% | 0.49x | 1.90x | ₹19.53 Million |
| 2015 | 15.13% | 13.75% | 0.57x | 1.94x | ₹42.26 Million |
| 2016 | 18.75% | 18.72% | 0.55x | 1.83x | ₹88.12 Million |
| 2017 | 19.60% | 19.05% | 0.56x | 1.82x | ₹114.87 Million |
| 2018 | 18.22% | 18.85% | 0.56x | 1.74x | ₹115.58 Million |
| 2019 | 23.42% | 23.34% | 0.59x | 1.69x | ₹238.21 Million |
| 2020 | 14.51% | 15.92% | 0.48x | 1.91x | ₹90.64 Million |
| 2021 | 15.08% | 16.06% | 0.52x | 1.80x | ₹115.99 Million |
| 2022 | 15.12% | 16.73% | 0.42x | 2.16x | ₹133.22 Million |
| 2023 | 9.11% | 10.01% | 0.49x | 1.87x | ₹-26.11 Million |
| 2024 | 6.47% | 6.20% | 0.46x | 2.27x | ₹-102.90 Million |
| 2025 | 8.75% | 8.84% | 0.48x | 2.08x | ₹-39.38 Million |
Industry Comparison
This section compares Hester Biosciences Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $12,445,167,922
- Average return on equity (ROE) among peers: 14.66%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Hester Biosciences Limited (HESTERBIO) | ₹3.51 Billion | 32.57% | 0.92x | $40.94 Million |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $802.45 Million | 7.70% | 1.12x | $11.20 Million |
| Aarti Drugs Limited (AARTIDRUGS) | $1.12 Billion | 12.32% | 2.74x | $149.72 Million |
| Abbott India Limited (ABBOTINDIA) | $42.33 Billion | 33.41% | 0.40x | $1.59 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $15.68 Billion | 32.33% | 0.16x | $1.46 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $7.20 Billion | -0.56% | 3.88x | $123.83 Million |
| Albert David Limited (ALBERTDAVD) | $2.44 Billion | 9.06% | 0.40x | $15.85 Million |
| Alivus Life Sciences Limited (ALIVUS) | $28.17 Billion | 17.24% | 0.21x | $333.13 Million |
| Alkem Laboratories Limited (ALKEM) | $23.74 Billion | 20.90% | 0.71x | $2.41 Billion |
| Alpa Laboratories Limited (ALPA) | $56.73 Million | 0.53% | 2.47x | $5.55 Million |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $2.91 Billion | 13.70% | 0.25x | $77.60 Million |